Review on Alzheimer’s disease: past, present and future

Jessy Rayathala; Kiran Kumar C; Venkatesh P

doi:10.37022/jiaps.v7i1.274

Rayathala Jessy B.Pharmacy final year student, Jagan’s Institute of Pharmaceutical Sciences, Nellore
C.Kiran Kumar Associate Professor, Dept.of Pharmacy Practice, Jagan’s Institute of Pharmaceutical Science, Nellore
P. Venkatesh Principal Jagan’s Institute of Pharmaceutical Science, Nellore

DOI https://doi.org/10.37022/jiaps.v7i1.274

Abstract

Alzheimer’s disease is a progressive neurodegenerative disorders that is the six leading Cause of death and the most common cause of dementia worldwide. The most common cause of dementia is Alzheimer’s disease (AD). Accounting for nearly 60 to 80 % of all cases. AD is the six leading cause of death with an estimated prevalence of nearly 30 million people worldwide. Age is the most important risk factor for AD, with an exponential increase in prevalence from 3 to 32 % from the ages 65 to 85 years old. An estimated 5.6 million individuals over the age of 65 suffer from AD in the United States, a number projected to nearly triple to 13.8 million by 2050 due to increase in population. The 2000s ushered in a focus on the study of prodromal stages of neurodegerative disease before the full – blown dementia syndrome. The current decades have been the rise of imaging and other biomarkers to characterize preclinical disease before the development of significant cognitive decline. Finally, we suggest future directions and predictions for dementia related research and potential therapeutic interventions.

Keywords: Alzheimer’s disease, neurodegenerative, Etiology, Electromyogram, hippocampal, Donepezil

Downloads

Download data is not yet available.

References

1. W. Barker et al., Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis. Assoc. Disord. 16, 203–212 (2002).
2. De-Paula V.J., Radanovic M., Diniz B.S., Forlenza O.V. Alzheimer’s disease. Sub-Cell. Biochem. 2012; 65:329–352. doi: 10.1007/978-94-007-5416-4_14.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 2. Washington, DC: American Psychiatric Association; 1968.
4. Dubois B., Hampel H., Feldman H.H., Scheltens P., Aisen P., Andrieu S., Bakardjian H., Benali H., Bertram L., Blennow K., et al. Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimer’s Dement. J. Alzheimer’s Assoc. 2016; 12:292–323. doi: 10.1016/j.jalz.2016.02.002.
5. Kumar A., Sidhu J., Goyal A. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2020. [(Accessed on 8 December 2020)].
6. Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: An overview. Ann Indian Acad Neurol. 2008; 11(1):13–19.
7. Kumar A, Singh A, Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol Rep. 2015; 67(2):195–203.
8. Goedert M. Alzheimer’s and Parkinson’s diseases: the prion concept in relation to assembled Aβ, tau, and α-synuclein. Science. 2015; 349(6248):1255555. doi:10.1126/science.1255555.
9. Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol. 2005; 4:771–80. [PubMed] [Google Scholar] [Ref list] mechanistically cr
10. Mechanistically critical relationship between cell-cycle re-entry, oxidative stress, and neuronal demise was recently postulated (Zhu et al 2004).
11. Zhu X, Raina AK, Perry G, Smith MA. Alzheimer’s disease: The two-hit hypothesis. Lancet Neurol. 2004; 3:219–26. [PubMed] [Google Scholar
12. Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, et al. Randomized trial of verubecestat for prodromal alzheimer's disease. N Engl J Med. (2019) 380:1408–20. doi: 10.1056/NEJMoa1812840
13. Systematic review and meta-analysis. J Alzheimers Dis. (2017) 60:401–25. doi: 10.3233/JAD- 170424
14. Armstrong R.A. Risk factors for Alzheimer’s disease. Folia Neuropathol. 2019; 57:87–105. doi: 10.5114/fn.2019.85929.
15. Anand P., Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch. Pharmacal Res. 2013; 36:375–399. doi: 10.1007/s12272-013-0036-3. [PubMed] [CrossRef] [Google Scholar] [Ref list]
16. Van Bulck M, Sierra-Magro A, Alarcon-Gil J, Perez- Castillo A, Morales-Garcia JA. Novel approaches for the treatment of Alzheimer’s and Parkinson’s disease. International Journal of Molecular Sciences. 2019 Jan; 20(3):719.
17. Jiang C, Li G, Huang P, Liu Z, Zhao B. The gut microbiota and Alzheimer’s disease. Journal of Alzheimer’s disease. 2017 Jan 1; 58(1):1-5
18. Hardy J Amyloid, the presenilins and Alzheimer’s disease. Trends neurosci 1997; 20154-159
19. Schachter, A.S; Davis, K. L Alzheimer’s Disease Dialogues Clin. Neurosci. 2000,2,91-100.